MASH: the liver evidence

The liver data that made survodutide stand out

If obesity is survodutide marquee program, MASH is its most distinctive one. Metabolic dysfunction-associated steatohepatitis is a fatty-liver disease with inflammation and scarring, and it is a growing driver of liver transplants. This unit explains the disease, walks the landmark Phase 2 MASH trial, and shows why a trial that moved inflammation, with a numerical fibrosis trend alongside it, put survodutide near the top of investigational liver drugs.

We also keep the caveat visible: these are strong Phase 2 numbers, and Phase 3 confirmation is still to come.